[PDF][PDF] Clinical setbacks for toll-like receptor 9 agonists in cancer
TTMDT MyD88, M NF-κB - NATURE BIOTECHNOLOGY, 2007 - academia.edu
Clinicalsetbacksfortoll-like receptor9agonistsincancer Page 1 NATUREBIOTECHNOLOGYVOLUME25NUMBER8AUGUST2007
825 Clinicalsetbacksfortoll-like receptor9agonistsincancer InJune,Pfizerdroppedaclinicalprogramin
non-smallcelllungcancerforPF-3512676,a CpGoligodeoxynucleotide(ODN)drugthat
activatedtoll-likereceptor9(TLR9)ofthe immunesystem.Whilebeingtestedinphase2
and3trialstogetherwithavarietyofchemotherapyagents,aninterimanalysisofthetwo
phase3trialsofPF-3512676showeditfailed toyieldclinicaloutcomesbetterthanthose …
825 Clinicalsetbacksfortoll-like receptor9agonistsincancer InJune,Pfizerdroppedaclinicalprogramin
non-smallcelllungcancerforPF-3512676,a CpGoligodeoxynucleotide(ODN)drugthat
activatedtoll-likereceptor9(TLR9)ofthe immunesystem.Whilebeingtestedinphase2
and3trialstogetherwithavarietyofchemotherapyagents,aninterimanalysisofthetwo
phase3trialsofPF-3512676showeditfailed toyieldclinicaloutcomesbetterthanthose …